Skip to main content
. 2019 Apr 16;4(7):987–994. doi: 10.1016/j.ekir.2019.04.010

Figure 2.

Figure 2

Weekly vitamin D receptor activators (VDRA) and etelcalcetide (ETEL) dose during the efficacy-assessment phase (EAP) by baseline intact parathyroid hormone (PTH) strata. Data presented as median, 25th percentile and 75th percentile (box) and minimum maximum dose (whiskers). VDRA dose is presented as i.v. paricalcitol equivalents. PBO, placebo.